Participant Attrition Risk
Attrition risk models use attendance patterns, diary compliance, and travel burden to flag participants who may benefit from additional retention support.
Custom Software
AI Clinical Trial Dropout Prediction Software Development
AI clinical trial dropout prediction software applies machine learning to visit attendance, protocol burden, site performance, and engagement data to identify participants and sites at elevated risk of attrition, so retention support can be offered. It is never used to screen out likely dropouts, which would bias trials and disadvantage the populations research most needs to include.
Retention failure is expensive and, more importantly, distorts evidence: when attrition concentrates among specific populations, the resulting data describes who stayed rather than who was studied. Taction Software builds AI clinical trial dropout prediction for retention support only, with enrollment exclusion designed out rather than merely discouraged.
Tell Us Your Requirements
Our experts are ready to understand your business goals.
Trusted Partners
Trusted by Industry Leaders Worldwide
Recognition
Awards & Recognitions
What Is AI Clinical Trial Dropout Prediction
AI clinical trial dropout prediction refers to machine learning applied to trial operations data: visit attendance patterns, protocol burden, travel distance, diary compliance, site staffing, and communication engagement, to forecast attrition risk at both participant and site level. The legitimate use is directing retention resources toward participants who face barriers. The illegitimate use is enrollment screening, which would introduce selection bias and systematically exclude populations already underrepresented in research. This work sits inside our broader healthcare AI practice.
Site Performance Monitoring
Site performance modeling identifies sites with elevated dropout, distinguishing site process problems from population differences before any corrective action.
Protocol Burden Analysis
Protocol burden analysis quantifies visit frequency, procedure intensity, and diary requirements against observed attrition, informing amendment discussions.
Engagement Signal Tracking
Communication response and portal use provide early engagement signals, connecting with patient engagement app development approaches.
Retention Intervention Routing
Flags route to retention support including transport assistance, visit rescheduling, and coordinator outreach, delivered by study staff who decide what each participant needs.
Prohibited Use Boundaries
Predictions are never used for enrollment screening or exclusion. Screening out likely dropouts biases trials and excludes underrepresented populations.
Core AI Clinical Trial Dropout Services
Our AI clinical trial dropout services cover data integration, retention modeling, site analytics, intervention workflow, and validated system delivery. Trial software carries compliance obligations most healthcare AI does not, since systems supporting regulatory submissions fall under 21 CFR Part 11 expectations for audit trails, electronic signatures, and validation. We scope that from the start. Engagements typically open with a review of available operational data across EDC, CTMS, and eCOA systems. Deliverables are structured so clinical operations, data management, and quality assurance can review independently.
01
Trial Systems Integration
We integrate EDC and CTMS data alongside eCOA and visit scheduling, since attrition signal is distributed across systems that rarely talk to each other.
02
Retention Model Development
Development produces participant and site models validated on historical trials, with subgroup reporting across age, distance, and demographic factors.
03
Site Analytics Delivery
Site dashboards distinguish process problems from population differences, so monitoring visits target sites where intervention will actually help.
04
Retention Workflow Design
We design intervention routing with clinical operations, matching flags to support the study budget can actually deliver.
05
Part 11 Validated Delivery
Systems supporting regulatory submissions require validation. Our 21 CFR Part 11 for AI work covers audit trail and validation requirements.
06
Trial Data Platform Context
Retention analytics sit alongside broader trial data work, connecting with clinical trials AI capabilities across the study lifecycle.
Benefits of AI Clinical Trial Dropout Prediction
The benefits of AI clinical trial dropout prediction concentrate in earlier retention intervention, better site oversight, and evidence for protocol design decisions. Retention problems are typically recognized after attrition has already occurred, when the affected participants are gone. Site-level modeling also separates genuine process problems from population differences, which conventional enrollment metrics conflate. We publish no figures on retention improvement or cost savings, because those depend on your protocol, population, and intervention budget.
Earlier Retention Intervention
Flagging participants before dropout allows transport support or rescheduling while the participant is still enrolled and reachable.
Better Site Oversight
Distinguishing site process issues from population differences directs monitoring effort where corrective action will change outcomes.
Evidence for Protocol Design
Quantifying protocol burden against attrition gives sponsors evidence for amendment decisions and informs design of subsequent studies.
Improved Data Completeness
Reduced attrition improves dataset completeness, which matters more for analysis validity than for enrollment economics alone.
Equity in Retention
Subgroup reporting reveals whether attrition concentrates in specific populations, surfacing representation loss that aggregate rates conceal.
Real World Evidence Continuity
Retention analytics support longitudinal data quality, connecting with real world evidence platform work for follow-up completeness.
Our AI Clinical Trial Dropout Process
We deliver AI clinical trial dropout projects in gated phases so clinical operations and quality stakeholders approve direction before engineering cost accumulates. Discovery establishes intended use, data availability across trial systems, validation requirements, and the explicit boundary that predictions support retention rather than selection. Development is iterative with clinical operations review. Where the system supports regulatory submissions, validation documentation is produced alongside development rather than assembled afterward.
Discovery and Use Boundary Definition
Discovery defines intended use and documents that predictions support retention only, never enrollment screening, with that boundary enforced in system design.
Trial Data Assessment
We evaluate data availability across EDC, CTMS, and eCOA systems, since attrition signal is fragmented and integration feasibility varies by vendor.
Model Development and Validation
Development runs to validation on historical studies, reporting performance by participant subgroup and site type rather than a single aggregate figure.
Equity Review
Models pass an equity review, since attrition risk correlates with distance, income, and caregiving burden, and flagging must not become a proxy for exclusion.
Retention Design With Operations
We design intervention routing with clinical operations, ensuring flags connect to support that is funded and deliverable within the study.
Validated Deployment
Where submissions are supported, deployment follows computer system validation with documented testing, audit trails, and change control.
Technology and Compliance
Trial software handles participant data under HIPAA where applicable, plus GCP obligations and 21 CFR Part 11 requirements where systems support regulatory submissions. Taction holds ISO 27001 certification and follows HIPAA-aligned engineering practice. Part 11 imposes audit trail, electronic signature, and validation requirements that shape architecture substantially. The ethical boundary requiring the most attention is enrollment: using dropout prediction to screen candidates would improve completion rates while biasing results and excluding populations research already underrepresents.
HIPAA-Aligned Engineering
Builds apply encryption in transit and at rest, role-based access, and complete audit logging. Our HIPAA compliance software development practice defines these controls.
21 CFR Part 11 Alignment
Part 11 requires audit trails, electronic signature controls, and computer system validation where systems support submissions, which we build rather than retrofit.
GCP and IRB Considerations
GCP expectations and IRB oversight apply to how predictions are used with participants, and intended use should be described in protocol documentation.
Enrollment Screening Prohibition
Enrollment exclusion is technically prevented. Predictions are unavailable to screening workflows, since selection use would bias trials and reduce representation.
Equity and Representation
Subgroup monitoring is required, since attrition concentrating in specific populations damages evidence validity beyond its effect on completion rates.
Deployment Security
Deployments run on-premise, in your cloud tenancy, or hybrid, with network segmentation, signed container images, and documented penetration testing before release.
Why Choose Taction Software
Taction Software was founded in 2013 and has spent over 12 years building healthcare software, delivering more than 200 healthcare projects from four US offices in Chicago, Cheyenne, Austin, and Sacramento, with ISO 27001 certification. Our relevant commitment here is refusing the obvious commercial application. Dropout prediction would sell more easily as an enrollment screening tool, and we will not build that, because it would improve trial metrics by making the evidence less representative. Our leadership brings more than 20 years of personal experience in the field.
01
Retention Only, By Design
We prevent enrollment screening use technically rather than discouraging it in documentation, because the commercial temptation here is obvious.
02
Validated System Delivery
We build Part 11 audit trails, validation documentation, and change control from the start where systems support regulatory submissions.
03
Established Healthcare Focus
Founded in 2013, we have concentrated on healthcare rather than treating it as one vertical among several, producing depth in clinical data systems.
04
Trial Data Integration
We integrate EDC and CTMS systems where vendors permit, handling the fragmentation that makes retention signal hard to assemble.
05
Equity in Evidence
We monitor subgroup attrition, since representation loss damages evidence validity in ways aggregate completion rates entirely conceal.
06
Certified Security Posture
ISO 27001 certification and HIPAA-aligned engineering mean security controls are documented and auditable, supporting sponsor and CRO vendor assessment.
Pricing
AI clinical trial dropout pricing depends on scope, trial system integration breadth, validation requirements, and whether site analytics are included. A participant retention model on one study costs considerably less than a portfolio platform with Part 11 validation and cross-study site analytics. Validation documentation is a meaningful cost component where submissions are supported, and we scope it explicitly. Discovery produces an itemized, fixed-scope estimate with phase-level breakdown. Cloud infrastructure and trial system licensing are separate from engineering and itemized clearly.
MVP or Single Module
An MVP delivering participant retention flags for one study typically runs $40,000 to $80,000, validating utility before portfolio scope.
Full Platform Build
A full platform with site analytics, protocol burden analysis, and intervention workflow typically falls between $80,000 and $200,000.
Enterprise Deployment
Enterprise engagements covering portfolio deployment, Part 11 validation, and multi-system integration start at $200,000 and scale with study count.
Discovery Phase Scoping
Discovery is a paid, time-boxed phase producing an itemized estimate, architecture plan, and validation requirement assessment. It is separable so you can evaluate our work first.
Cost Drivers to Expect
Validation scope, trial system integration count, portfolio breadth, and decentralized trial requirements are the largest variables, identified during discovery.
Ongoing Support Costs
Post-launch revalidation, model monitoring, system updates, and support are quoted separately as a retainer sized to your active study count.
Get Started
If you are evaluating AI clinical trial dropout prediction for participant retention, site oversight, or protocol burden analysis, the fastest next step is a discovery call with our team. We will review data availability across your trial systems, assess validation requirements, and return an itemized, fixed-scope estimate. Contact us to schedule that conversation.
FAQs
Frequently Asked Questions
Sponsors and CROs evaluating AI clinical trial dropout prediction usually ask whether it can inform enrollment, how Part 11 applies, and what data is required. The answers below reflect how we scope these projects. The enrollment question comes up frequently and the answer does not change.
No, and we prevent it technically. Screening on predicted attrition introduces selection bias and systematically excludes people facing distance, income, or caregiving barriers, who are already underrepresented in research. It would improve completion metrics while making the evidence less generalizable. Predictions are unavailable to enrollment workflows.
If the system supports regulatory submissions, yes, which means audit trails, electronic signature controls, and computer system validation. That shapes architecture substantially and is a real cost component. Where the system is used purely for internal operations, requirements are lighter, and we assess that during discovery.
Visit attendance, protocol schedule, travel distance, diary or eCOA compliance, and communication engagement, distributed across EDC, CTMS, and eCOA systems. Integration feasibility varies by vendor and contract, so we confirm access during discovery rather than assuming the data can be assembled.
An MVP for one study runs $40,000 to $80,000. A full platform with site analytics typically falls between $80,000 and $200,000. Enterprise portfolio deployments with Part 11 validation start at $200,000. Validation documentation is scoped explicitly as it materially affects cost.
Yes, with different inputs. Decentralized attrition is driven by technology engagement, device compliance, and remote assessment burden rather than visit travel, so models built for site-based studies transfer poorly. We build to the trial model rather than adapting one configuration.
It will identify sites with elevated attrition and help distinguish process problems from population differences, which is the useful distinction. Site decisions belong to clinical operations, and a site serving a harder-to-retain population should not be penalized for the population it recruits.